<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJMCe</journal-id><journal-title-group><journal-title>Hans Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="epub">2331-8287</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJMCe.2019.72004</article-id><article-id pub-id-type="publisher-id">HJMCe-30085</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJMCe20190200000_32145394.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject><subject> 化学与材料</subject></subj-group></article-categories><title-group><article-title>
 
 
  二芳基甲酮化合物抑制SHP2生物活性研究
  Biological Evaluation of Diaryl Ketones against SHP2
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>范</surname><given-names>秋玥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>传涛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>文龙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>江南大学药学院，江苏 无锡</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>04</month><year>2019</year></pub-date><volume>07</volume><issue>02</issue><fpage>19</fpage><lpage>24</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   蛋白酪氨酸磷酸酶SHP2在细胞信号转导过程中起着重要的作用，参与细胞的生长、分化、代谢、运动和凋亡，作为潜在的抗肿瘤治疗靶点备受关注。二芳基甲酮化合物在生物活性分子中广泛存在，是基于片段的药物发现策略(fragment-based drug discovery, FBDD)的理想结构模块。本试验研究了二芳基甲酮化合物在SHP2PTP模型上的构效关系，结果表明4-甲氧基二苯甲酮(1l)、(2-氟苯基)-(2-噻吩基)甲酮(1u)以及(2,4-二甲氧基苯基)-(2-氟苯基)甲酮(1v)在20 μg/mL的浓度下，对SHP2PTP分别表现了53.90% &#177; 8.35%、47.03% &#177; 4.85%和50.08% &#177; 3.90%的抑制率，为后续基于片段的SHP2抑制剂研究工作奠定了一定的基础。 SHP2 is of importance for the regulation of essential cellular processes that control growth, diffe-rentiation, metabolism, motility and apoptosis and has potential as a drug target. Diaryl ketones are frequently used as core motifs for fragment-based drug discovery (FBDD). A series of diarylketones was evaluated as a new class of inhibitors against Scr homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). Among them, (4-methoxyphenyl) (phenyl) methanone (1l), (2-fluorophenyl) (thiophen-2-yl) methanone (1u), (2,4-dimethoxyphenyl) (2-fluorophenyl) methanone (1v) exhibited enzyme inhibitory ratio at the dose of 20 μg/mL with 53.90% &#177; 8.35%, 47.03% &#177; 4.85% and 50.08% &#177; 3.90% respectively and these results would be highly advantageous for fragment-based drug discovery to obtain selective SHP2 inhibitors.
    
  
 
</p></abstract><kwd-group><kwd>二芳基甲酮，SHP2PTP，抑制剂，构效关系, Diaryl Ketones</kwd><kwd> SHP2</kwd><kwd> Inhibitors</kwd><kwd> Structure-Activity Relationships (SARs)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>二芳基甲酮化合物抑制SHP2生物活性研究<sup> </sup></title><p>范秋玥，张传涛，王文龙<sup>*</sup></p><p>江南大学药学院，江苏 无锡</p><p><img src="//html.hanspub.org/file/3-3070077x1_hanspub.png" /></p><p>收稿日期：2019年4月14日；录用日期：2019年4月28日；发布日期：2019年5月6日</p><disp-formula id="hanspub.30085-formula60"><graphic xlink:href="//html.hanspub.org/file/3-3070077x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>蛋白酪氨酸磷酸酶SHP2在细胞信号转导过程中起着重要的作用，参与细胞的生长、分化、代谢、运动和凋亡，作为潜在的抗肿瘤治疗靶点备受关注。二芳基甲酮化合物在生物活性分子中广泛存在，是基于片段的药物发现策略(fragment-based drug discovery, FBDD)的理想结构模块。本试验研究了二芳基甲酮化合物在SHP2<sup>PTP</sup>模型上的构效关系，结果表明4-甲氧基二苯甲酮(1l)、(2-氟苯基)-(2-噻吩基)甲酮(1u)以及(2,4-二甲氧基苯基)-(2-氟苯基)甲酮(1v)在20 μg/mL的浓度下，对SHP2<sup>PTP</sup>分别表现了53.90% &#177; 8.35%、47.03% &#177; 4.85%和50.08% &#177; 3.90%的抑制率，为后续基于片段的SHP2抑制剂研究工作奠定了一定的基础。</p><p>关键词 :二芳基甲酮，SHP2<sup>PTP</sup>，抑制剂，构效关系</p><disp-formula id="hanspub.30085-formula61"><graphic xlink:href="//html.hanspub.org/file/3-3070077x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-3070077x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-3070077x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>二芳基甲酮结构片段广泛存在于天然产物和生物活性分子中 [<xref ref-type="bibr" rid="hanspub.30085-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.30085-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.30085-ref3">3</xref>]，代表性分子包括非甾体抗炎药(NSAID)酮洛芬 [<xref ref-type="bibr" rid="hanspub.30085-ref4">4</xref>]、广谱人类驱虫药甲苯咪唑 [<xref ref-type="bibr" rid="hanspub.30085-ref5">5</xref>]、经典脂质调节剂非诺贝特 [<xref ref-type="bibr" rid="hanspub.30085-ref6">6</xref>] 和促尿酸排泄药苯溴马隆(BBR) [<xref ref-type="bibr" rid="hanspub.30085-ref7">7</xref>] 等(图1)。研究表明，含二芳基苯甲酮结构片段的化合物对人单核细胞白血病癌细胞系有一定的细胞毒性 [<xref ref-type="bibr" rid="hanspub.30085-ref8">8</xref>]；与肿瘤坏死因子相关的凋亡诱导配体结合后，诱导 Jurkat细胞凋亡 [<xref ref-type="bibr" rid="hanspub.30085-ref9">9</xref>]；可以作为血管生成抑制剂起到抑癌作用 [<xref ref-type="bibr" rid="hanspub.30085-ref10">10</xref>]；也可以作为转运P-糖蛋白(P-gp/ABCB1)抑制剂克服肿瘤多药耐药性 [<xref ref-type="bibr" rid="hanspub.30085-ref11">11</xref>] 。对于基于片段的药物发现策略而言 [<xref ref-type="bibr" rid="hanspub.30085-ref12">12</xref>]，二芳基甲酮在片段大小、溶解度以及类药性等方面表现了良好的物理化学性质，可以为创新药物研究提供良好的分子模块 [<xref ref-type="bibr" rid="hanspub.30085-ref13">13</xref>] 。</p><p>图1. 含二芳基甲酮骨架的药物</p><p>SHP2是由PTPN11编码的一种在体内广泛表达的蛋白酪氨酸磷酸酶，调节细胞内的蛋白磷酸化水平，参与多种细胞生命活动，包括细胞侵袭，细胞凋亡，细胞增殖，细胞周期等的信号传导 [<xref ref-type="bibr" rid="hanspub.30085-ref14">14</xref>] 。SHP2的过度活化与多种恶性疾病(如Noonan综合征、白血病、乳腺癌、肺癌、胃癌等)的发生发展有着密切的联系 [<xref ref-type="bibr" rid="hanspub.30085-ref15">15</xref>]，已经成为了肿瘤治疗领域的重要靶标 [<xref ref-type="bibr" rid="hanspub.30085-ref16">16</xref>] 。在前期的工作中，我们基于组合化学的理念，报道了连续化合成二芳基甲酮化合物的方法 [<xref ref-type="bibr" rid="hanspub.30085-ref17">17</xref>] 。本文以SHP2催化域蛋白(SHP2<sup>PTP</sup>)作为活性评价模型，在浓度20 g/mL的条件下，考察二芳基甲酮化合物对SHP2<sup>PTP</sup>的抑制效果，研究构效关系。实验结果表明，4-甲氧基二苯甲酮(1l)、(2-氟苯基)-(2-噻吩基)甲酮(1u)以及(2,4-二甲氧基苯基)-(2-氟苯基)甲酮(1v)对SHP2<sup>PTP</sup>分别表现了53.90% &#177; 8.35%、47.03% &#177; 4.85%和50.08% &#177; 3.90%的抑制率，为后续基于片段的SHP2抑制剂研究工作奠定了一定的基础。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 材料</title><p>实验材料：二芳基甲酮化合物由江南大学药学院药物化学实验室制备。</p><p>实验试剂：</p><p>HEPS、Tris-Base、NaCl、KCl、Tween-20、KH<sub>2</sub>PO<sub>4</sub>、乙二胺四乙酸(EDTA)、二硫苏糖醇(DTT)、Na<sub>2</sub>HPO<sub>4</sub>、二甲亚砜(DMSO)，购自国药集团化学试剂有限公司；</p><p>牛白蛋白(BSA)、氨苄青霉素、异丙基-β-D-硫代吡喃半乳糖苷(IPTG)、琼脂糖、TritonX-100、胰蛋白胨、酵母提取物等分子生物学试剂，购自上海生工生物工程公司；</p><p>菌株、质粒及蛋白：大肠杆菌感受态BL21及用于蛋白表达的质粒由国家新药筛选中心实验室提供，SHP2催化域蛋白(SHP2<sup>PTP</sup>:246-523AA)国家新药筛选中心实验室纯化；</p><p>底物：6,8-二氟-4-甲基-7-羟基香豆素磷酸酯(DiFMUP)，购自英潍捷基公司。</p><p>实验仪器(如表1)：</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Instruments and equipment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >仪器名称</th><th align="center" valign="middle" >公司名称</th></tr></thead><tr><td align="center" valign="middle" >恒温摇床</td><td align="center" valign="middle" >上海市智城仪器制造公司</td></tr><tr><td align="center" valign="middle" >37℃恒温培养箱</td><td align="center" valign="middle" >上海市福玛实验设备有限公司</td></tr><tr><td align="center" valign="middle" >Hitachi CRG冷冻高速离心机</td><td align="center" valign="middle" >日本日立公司</td></tr><tr><td align="center" valign="middle" >Envision多功能微孔板酶标仪</td><td align="center" valign="middle" >Molecular Devices (U.S.A)</td></tr></tbody></table></table-wrap><p>表1. 实验设备与仪器</p></sec><sec id="s4_2"><title>2.2. 实验方法</title><sec id="s4_2_1"><title>2.2.1. 蛋白的表达及纯化</title><p>将截短的SHP2<sup>PTP</sup>催化域蛋白表达重组质粒通过热激法转化到BL21感受态中，将菌液均匀涂布在含有氨苄青霉素的LB平板上，37℃恒温培养过夜。次日挑单克隆菌落接种于含有100 μg/mL的氨苄青霉素的LB液体培养基中，于37℃恒温250 rmp摇床上培养。监测菌液密度，当OD<sub>600</sub> = 0.6~0.8之间时，可加入0.5 mM的IPTG进行16℃低温180 rmp低转速诱导16小时。将诱导后的菌液离心收集，用平衡液(137 mM NaCl、1.5 mM KH<sub>2</sub>PO<sub>4</sub>、2.7 mM KCl、8 mM Na<sub>2</sub>HPO<sub>4</sub>、2 mM EDTA、2 mM DTT、1% TritonX-100)重悬，在冰浴的条件下用350W的超声强度超声2秒，停顿6秒裂解菌液40min。超声结束后于4℃离心菌液，收集上清，与GST-Beeds于4℃孵育2h或过夜后，用洗脱液(137 mM NaCl、1.5 mM KH<sub>2</sub>PO<sub>4</sub>、2.7 mM KCl、8 mM Na<sub>2</sub>HPO<sub>4</sub>、2 mM DTT、2 mM EDTA、10 mM还原性谷胱甘肽、50 mM Tris-Base pH = 8.0)将目的蛋白洗脱，用考马斯亮蓝G250染色，以100 μg/mL牛血清白蛋白为标准品检测蛋白浓度。</p></sec><sec id="s4_2_2"><title>2.2.2. 二芳基甲酮化合物对SHP2<sup>PTP</sup>活性抑制作用</title><p>化合物活性测试体系是国家新药筛选中心的标准化常规筛选体系；活性测试体系总体积为50 μL：10 μL待测化合物(20 μg/mL, 2% DMSO)、20 μL底物DiFMUP (25 μM)、20 μL SHP2<sup>PTP</sup> (2 nM)；活性测试反应Buffer：60 mM Heps pH = 7.2、75 mM NaCl、75 mM KCl、5 mM DTT、1 mM EDTA及0.05% Tween-20。反应在黑底384孔板中进行，用Buffer稀释蛋白及底物，将待测化合物与蛋白孵育10min后加入底物，立即在Envision上用动态法监测波长340 nm/450 nm处的荧光信号，通过荧光信号值曲线的斜率来判断去磷酸化反应的速率，进而测定目的蛋白的活性，观察化合物对酶活性的影响。</p></sec></sec></sec><sec id="s5"><title>3. 结果与讨论</title><p>本研究以Na<sub>3</sub>VO<sub>3</sub>作为阳性对照，评价二芳基甲酮化合物(1a-1v)对SHP2<sup>PTP</sup>的抑制活性，结果如表2所示。实验结果表明，当A环为苯基(1a-1o)，B环为苯基(1a)、甲基取代苯基(1b-1d)、氟代苯基(1e-1g)、间氯苯基(1h)、三氟甲基取代苯基(1i-1j)、萘基(1n)以及(1-氰乙基)苯基(1o)时，衍生物未产生抑制活性；当B环为对甲氧基苯基时，对甲氧基二苯甲酮(1l)对SHP2<sup>PTP</sup>的抑制率达到了53.90% &#177; 8.35%，抑制活性是间甲氧基二苯甲酮(1k)的5倍，是对氰基二苯甲酮(1m)的2倍。这些结果表明，B环上取代基的类型、取代基的位置，对活性产生影响。当A环为2-氟苯基时(1p-1v)，B环为对氯苯基(1p)、甲基取代苯基(1q-1r)以及间氟苯基(1s)时，没有抑制活性。值得注意的是，对2-氟-4'-甲氧基二苯甲酮(1t)的抑制活性明显低于4-甲氧基二苯甲酮(1l)，这一结果表明，A环为2-氟苯基，不利于抑制活性的提高。有意思的是，B环为噻吩基(1u)和2,3-二甲氧基苯环(1v)时，抑制活性显著提高，这些结果表明，B环为富电子芳香环，对提高抑制活性有力。遗憾的是，所有二芳基甲酮化合物对SHP2<sup>PTP</sup>的抑制活性明显低于阳性对照Na<sub>3</sub>VO<sub>3</sub>。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Inhibitory ratio of compounds diaryl ketones 1a-1v against SHP2PT</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >Comp</th><th align="center" valign="middle" >A</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >Inhibitory ratio(%)</th><th align="center" valign="middle" >Comp</th><th align="center" valign="middle" >A</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >Inhibitory ratio(%)</th></tr></thead><tr><td align="center" valign="middle" >1a</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x12_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x13_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >1.16 &#177; 5.94</td><td align="center" valign="middle" >1m</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x14_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x15_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >21.11 &#177; 2.45</td></tr><tr><td align="center" valign="middle" >1b</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x16_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x17_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−1.20 &#177; 3.74</td><td align="center" valign="middle" >1n</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x18_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x19_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >1.57 &#177; 0.02</td></tr><tr><td align="center" valign="middle" >1c</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x20_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x21_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−6.47 &#177; 3.48</td><td align="center" valign="middle" >1o</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x22_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x23_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−1.52 &#177; 5.06</td></tr><tr><td align="center" valign="middle" >1d</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x24_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x25_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−4.16 &#177; 4.79</td><td align="center" valign="middle" >1p</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x26_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x27_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−8.38 &#177; 2.65</td></tr><tr><td align="center" valign="middle" >1e</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x28_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x29_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−3.86 &#177; 2.39</td><td align="center" valign="middle" >1q</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x30_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x31_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−5.17 &#177; 2.19</td></tr><tr><td align="center" valign="middle" >1f</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x32_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x33_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−0.63 &#177; 4.42</td><td align="center" valign="middle" >1r</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x34_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x35_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−2.72 &#177; 2.74</td></tr><tr><td align="center" valign="middle" >1g</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x36_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x37_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−1.06 &#177; 4.26</td><td align="center" valign="middle" >1s</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x38_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x39_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−0.14 &#177; 3.97</td></tr><tr><td align="center" valign="middle" >1h</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x40_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x41_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >1.72 &#177; 3.17</td><td align="center" valign="middle" >1t</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x42_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x43_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >10.14 &#177; 4.29</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >1i</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x44_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x45_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >1.17 &#177; 4.06</th><th align="center" valign="middle" >1u</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x46_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x47_hanspub.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >47.03 &#177; 4.85</th></tr></thead><tr><td align="center" valign="middle" >1j</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x48_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x49_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >−5.45 &#177; 1.25</td><td align="center" valign="middle" >1v</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x50_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x51_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >50.08 &#177; 3.90</td></tr><tr><td align="center" valign="middle" >1k</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x52_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x53_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >10.66 &#177; 1.23</td><td align="center" valign="middle" >Na<sub>3</sub>VO<sub>3</sub></td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >95.38 &#177; 4.65</td></tr><tr><td align="center" valign="middle" >1l</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x54_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/3-3070077x55_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >53.90 &#177; 8.35</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 二芳基甲酮化合物1a-1v对SHP2<sup>PTP</sup>的抑制活性</p></sec><sec id="s6"><title>4. 结论</title><p>本文对二芳基甲酮化合物进行了抑制SHP2<sup>PTP</sup>生物活性的构效关系研究，发现4-甲氧基二苯甲酮(1l)、(2-氟苯基)-(2-噻吩基)甲酮(1u)以及(2,4-二甲氧基苯基)-(2-氟苯基)甲酮(1v)对SHP2<sup>PTP</sup>表现了一定的抑制活性，为基于片段的靶向SHP2抑制剂的研究工作提供了一些分子量小、类药性好的片段分子，为后续的研究提供了有利的信息。</p></sec><sec id="s7"><title>基金项目</title><p>国家自然科学基金面上项目(21772068)。</p></sec><sec id="s8"><title>文章引用</title><p>范秋玥,张传涛,王文龙. 二芳基甲酮化合物抑制SHP2生物活性研究 Biological Evaluation of Diaryl Ketones against SHP2[J]. 药物化学, 2019, 07(02): 19-24. https://doi.org/10.12677/HJMCe.2019.72004</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30085-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Keylor, M.H., Matsuura, B.S. and Stephenson, C.R.J. (2015) Chemistry and Biology of Resveratrol-Derived Natural Products. Chemical Reviews, 115, 8976-9027. &lt;br&gt;https://doi.org/10.1021/cr500689b</mixed-citation></ref><ref id="hanspub.30085-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Qi, X., Jiang, L.-B., Li, H.-P., et al. (2015) A Convenient Palladium-Catalyzed Carbonylative Suzuki Coupling of Aryl Halides with Formic Acid as the Carbon Monoxide Source. Chemistry—A European Journal, 21, 17650-17656.  
&lt;br&gt;https://doi.org/10.1002/chem.201502943</mixed-citation></ref><ref id="hanspub.30085-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rao, M.L.N. and Ramakrishna, B.S. (2017) Roodium-Catalyzed Directing-Group-Assisted Aldehydic C-H Arylations with Aryl Halides. European Journal of Organic Chemistry, No. 34, 5080-5093.  
&lt;br&gt;https://doi.org/10.1002/ejoc.201700881</mixed-citation></ref><ref id="hanspub.30085-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Smith, E.A., Marshall, J.G., Selph, S.S., et al. (2017) Nonsteroidal Anti-Inflammatory Drugs for Managing Postoperative Endodontic Pain in Patients Who Present with Preoperative Pain: A Systematic Review and Meta-Analysis. Journal of Endodontics, 43, 7-15. &lt;br&gt;https://doi.org/10.1016/j.joen.2016.09.010</mixed-citation></ref><ref id="hanspub.30085-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zimmermann, S.C., Tichy, T., Vavra, J., et al. (2018) N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. Journal of Medicinal Chemistry, 61, 3918-3929.  
&lt;br&gt;https://doi.org/10.1021/acs.jmedchem.7b01792</mixed-citation></ref><ref id="hanspub.30085-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Agarwal, V., Bajpai, M. and Sharma, A. (2018) Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects. Recent Patents on Drug Delivery &amp; Formulation, 12, 40-52. &lt;br&gt;https://doi.org/10.2174/1872211312666180105114644</mixed-citation></ref><ref id="hanspub.30085-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, J. (2018) Metabolic Activation-Based Design of Uricosuric Benzofuran Derivatives with Low Potential of Hepatotoxicity. Drug Metabolism and Pharmacokinetics, 33, S70-S70. &lt;br&gt;https://doi.org/10.1016/j.dmpk.2017.11.234</mixed-citation></ref><ref id="hanspub.30085-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cao, S.G., Wu, X.-H., Sim, K.Y., et al. (1998) Minor Coumarins from Calophyllum teysmannii var. inophylloide and Synthesis of Cytotoxic Calanone Derivatives. Helvetica Chimica Acta, 81, 1404-1416.  
&lt;br&gt;https://doi.org/10.1002/hlca.19980810549</mixed-citation></ref><ref id="hanspub.30085-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Takashima, J., Ikeda, Y., Komiyama, K., et al. (2007) New Con-stituents from the Leaves of Morinda citrifolia. Chemical and Pharmaceutical Bulletin, 55, 343-345. &lt;br&gt;https://doi.org/10.1248/cpb.55.343</mixed-citation></ref><ref id="hanspub.30085-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hornick, C.A., Myers, A., Sadowska-Krowicka, H., et al. (2003) Inhibi-tion of Angiogenic Initiation and Disruption of Newly Established Human Vascular Networks by Juice from Morinda citrifolia (noni). Angiogenesis, 6, 143-149.  
&lt;br&gt;https://doi.org/10.1023/B:AGEN.0000011800.04507.4b</mixed-citation></ref><ref id="hanspub.30085-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jabeen, I., Pleban, K., Rinner, U., et al. (2012) Structure-Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein. Journal of Medicinal Chemistry, 55, 3261-3273. &lt;br&gt;https://doi.org/10.1021/jm201705f</mixed-citation></ref><ref id="hanspub.30085-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">程俊飞, 盛春泉, 董国强. 基于片段的药物发现(FBDD)研究进展[J]. 中国药物化学杂志, 2018, 28(6): 504-510.</mixed-citation></ref><ref id="hanspub.30085-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Doweyko, A.M. and Wrobleski, S.T. (2005) Structural Comparison of p38 Inhibitor-Protein Complexes: A Review of Recent p38 Inhibitors Having Unique Binding Interactions. Current Topics in Medicinal Chemistry, 5, 1005-1016.  
&lt;br&gt;https://doi.org/10.2174/1568026054985894</mixed-citation></ref><ref id="hanspub.30085-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Zhang, F. and Niu, R. (2015) Functions of Shp2 in Cancer. Journal of Cellular and Molecular Medicine, 78, 2075-2083. &lt;br&gt;https://doi.org/10.1111/jcmm.12618</mixed-citation></ref><ref id="hanspub.30085-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Frankson, R., Yu, Z.H., Bai, Y., Li, Q., Zhang, R.Y., et al. (2017) The-rapeutic Targeting of Oncogenic Tyrosine Phosphatases. Cancer Research, 7, 5701-5705. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-17-1510</mixed-citation></ref><ref id="hanspub.30085-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y.N., LaMarche, M.J., Chan, H.M., Fekkes, P., Carcia-Fortanet, J., et al. (2016) Allosteric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyro-sine Kinases. Nature, 535, 148-152.</mixed-citation></ref><ref id="hanspub.30085-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, C.T., Zhu, R., Wang, Z., et al. (2019) Continuous Flow Synthesis of Diaryl Ketones by Coupling of Aryl Grignard Reagents with Acyl Chlorides under Mild Conditions in the Ecofriendly Solvent 2-Methyltetrahydrofuran. RSC Advances, 9, 2199-2204. &lt;br&gt;https://doi.org/10.1039/C8RA07447J</mixed-citation></ref></ref-list></back></article>